Perspectives on HAART: switch maintenance therapy

Area of Science:

• Antiretroviral Therapy
• HIV Treatment Adherence
• Metabolic Syndrome in HIV

Background:

• Highly active antiretroviral therapy (HAART) regimens often include protease inhibitors (PIs).
• Discontinuing PIs can improve patient adherence and quality of life.
• Metabolic complications are a concern in patients on long-term HAART.

Purpose of the Study:

• To evaluate the impact of switching from PIs in HAART on adherence, metabolic profiles, and virological suppression.
• To identify patient subgroups who may benefit from PI discontinuation.
• To assess the potential risks and benefits of switching antiretroviral therapy components.

Main Methods:

• Review of switch studies comparing PI-based HAART with alternative regimens.
• Analysis of adherence data, metabolic parameters (insulin resistance, triglycerides), and virological outcomes.
• Assessment of side effect profiles associated with PI discontinuation and alternative drug classes.

Main Results:

• Switching from PIs is associated with improved adherence and quality of life.
• A trend towards improved metabolic profiles, particularly reduced insulin resistance and triglyceride levels, is observed after PI discontinuation.
• Virological suppression can be maintained if achieved for at least six months prior to the switch and in patients without prior suboptimal HAART exposure.
• Peripheral wasting is linked to nucleoside analogues, and modification of HAART is not recommended for isolated fat accumulation.

Conclusions:

• Discontinuing PIs in HAART can enhance adherence and metabolic health while preserving virological suppression in selected patients.
• Switching may preserve PIs for future use.
• Potential side effects of switching include hypersensitivity, rashes, and hepatic or neuropsychiatric events, requiring careful monitoring.